Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study

Zhanchou Zhang, Jinguo Zhai, Qinling Wei, Jingfeng Qi, Xiaofeng Guo, Jingping Zhao, Zhanchou Zhang, Jinguo Zhai, Qinling Wei, Jingfeng Qi, Xiaofeng Guo, Jingping Zhao

Abstract

Background: A combination of psychosocial interventions and medications has been highly recommended as a successful treatment package for schizophrenia. Its cost-effectiveness has not been fully explored yet. The aim of the present analysis was to evaluate the cost-effectiveness of antipsychotics combined with psychosocial treatment and treatment as usual for patients with early-stage schizophrenia.

Method: Patients with schizophrenia (N = 1, 268) were assigned to the combination of medication and psychosocial intervention or treatment as usual for up to 12 months. Cost analysis included direct medical costs, direct nonmedical costs and indirect costs. Quality-adjusted life year (QALY) ratings were assessed with Short- Form 6D.

Results: Average monthly psychosocial intervention costs for combined treatment were higher than treatment as usual (p = 0.005), but no significant differences were found in direct costs, indirect costs, and total costs between two groups (all p-values ≥ 0.556). Combined treatment was associated with significant higher QALY ratings than treatment as usual (p = 0.039). Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALY ratings at an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained.

Conclusions: Despite some limitations, our results supported that medication combined with psychosocial treatment was more cost-effective than treatment as usual for patients with early-stage schizophrenia.

Trial registration: clinicaltrials.gov Identifier: NCT00654576.

Figures

Figure 1
Figure 1
Flowchart of participation in the study.
Figure 2
Figure 2
Average monthly quality-adjusted life year rating.

References

    1. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122–1129. doi: 10.4088/JCP.v66n0906.
    1. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279–293. doi: 10.1093/oxfordjournals.schbul.a007078.
    1. WHO . The Global Burden of Disease: 2004 Update. Geneva: WHO; 2008.
    1. Li JF, Lambert CE, Lambert VA. Predictors of family caregivers’ burden and quality of life when providing care for a family member with schizophrenia in the People’s Republic of China. Nurs Health Sci. 2007;9:192–198. doi: 10.1111/j.1442-2018.2007.00327.x.
    1. Yang Z, Liu ML. The economic cost of schizophrenia [in Chinese] Chin Health Econ Mag. 2003;22:28–29.
    1. Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res. 2008;100:108–119. doi: 10.1016/j.schres.2007.12.468.
    1. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry. 2005;162:2220–2232. doi: 10.1176/appi.ajp.162.12.2220.
    1. Rosenbaum B, Valbak K, Harder S, Knudsen P, Køster A, Lajer M, Lindhardt A, Winther G, Petersen L, Jørgensen P, Nordentoft M, Andreasen AH. The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis. Br J Psychiatry. 2005;186:394–399. doi: 10.1192/bjp.186.5.394.
    1. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346–351. doi: 10.1192/bjp.184.4.346.
    1. Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23(Suppl 1):75–89. doi: 10.2165/00019053-200523001-00007.
    1. Barnett PG, Scott JY, Krystal JH, Rosenheck RA, CSP 555 Research Group Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2005;73:696–702. doi: 10.4088/JCP.11m07070.
    1. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J, CATIE Study Investigators Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080–2089. doi: 10.1176/appi.ajp.163.12.2080.
    1. Patel A, Knapp M, Romeo R, Reeder C, Matthiasson P, Everitt B, Wykes T. Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis. Schizophr Res. 2010;120:217–224. doi: 10.1016/j.schres.2009.12.003.
    1. Phanthunane P, Vos T, Whiteford H, Bertram M. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc. 2011;9:6. doi: 10.1186/1478-7547-9-6.
    1. Guo XF, Zhai JG, Liu ZN, Fang MS, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z, Ma C, He X, Guo T, Xie S, Wu R, Xue Z, Chen J, Twamley EW, Jin H, Zhao J. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry. 2010;67:895–904. doi: 10.1001/archgenpsychiatry.2010.105.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis I Disorders–Clinician Version (SCID-CV) Washington, DC: American Psychiatry Press; 1997.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261.
    1. Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009;12(Suppl 3):66–69. doi: 10.1111/j.1524-4733.2009.00630.x.
    1. McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, Ruggeri M, Giessler A, Puschner B, Thornicroft G. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12:27–31.
    1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292. doi: 10.1016/S0167-6296(01)00130-8.
    1. McGhee SM, Brazier J, Lam CLK, Wong LC, Chau J, Cheung A, Ho A. Quality-adjusted life years: population-specific measurement of the quality component. Hong Kong Med J. 2011;17(Suppl 6):17–21.
    1. Lam CLK, Brazier J, McGhee SM. Valuation of the SF-6D health states is feasible, acceptable, reliable, and valid in a Chinese population. Value Health. 2008;11:295–303. doi: 10.1111/j.1524-4733.2007.00233.x.
    1. Lam ETP, Lam CLK, Lo YYC, Grandek B. Psychometrics and population norm of the Chinese (HK) SF-36 Health Survey version 2. HK Pract. 2008;30:185–198.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville: Dept of Health, Education, and Welfare; 1976.
    1. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766–771. doi: 10.1001/archpsyc.1976.01770060086012.
    1. Pai S, Kapur RL. The burden on the family of a psychiatric patient: development of an interview schedule. Br J Psychiatry. 1981;138:332–335. doi: 10.1192/bjp.138.4.332.
    1. Hoch JS, Briggs A, Willan A. Something old, something new, something borrowed, something blue: a framework for the marriage of health economics and cost effectiveness analysis. Health Econ. 2002;11:415–430. doi: 10.1002/hec.678.
    1. Chisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, Mendis N, Ayuso-Mateos JL, Saxena S. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ. 2008;86:542–551. doi: 10.2471/BLT.07.045377.
    1. Zhai J, Guo X, Chen M, Zhao J, Su Z. An investigation of economic costs of schizophrenia in two areas of China. Int J Ment Health Syst. 2013;15:26. doi: 10.1186/1752-4458-7-26.
    1. Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res. 2010;116:118–125. doi: 10.1016/j.schres.2009.09.026.
    1. van den Brink M, van den Hout WB, Stiggelbout AM, van de Velde CJ, Kievit J. Cost measurement in economic evaluations of health care: whom to ask? Med Care. 2004;42:740–746. doi: 10.1097/01.mlr.0000132351.78009.a1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe